HRT for Women: What the Evidence Actually Says

I have been practicing bioidentical hormone replacement therapy for more than ten years. I have watched women come through my door who were told by their primary care physicians — confidently, sometimes harshly — that hormone replacement would give them cancer or a heart attack. I have watched those same women suffer through years of hot flashes, insomnia, vaginal atrophy, cognitive fog, mood instability, and accelerated bone loss because of a decision made by someone citing a 2002 study that the scientific community has since substantially reinterpreted. It is one of the most consequential miscommunications in modern medicine, and it is still happening.

Here is what the Women's Health Initiative actually found, and what it didn't. The WHI used conjugated equine estrogen — derived from horse urine — combined with a synthetic progestin called medroxyprogesterone acetate. It enrolled women with an average age of 63, many of whom were more than a decade past menopause onset. When people say 'the study that scared everyone away from HRT,' they are talking about results generated with non-bioidentical hormones in women who were starting treatment far outside what we now know to be the therapeutic window. The WHI findings do not map directly onto a 51-year-old woman starting estradiol and bioidentical progesterone within five years of her last menstrual period. These are fundamentally different clinical scenarios.

The critical window hypothesis is one of the most important concepts in women's health that most women have never heard of. Initiating HRT within ten years of menopause onset — or before age 60, whichever comes first — is associated with cardiovascular protection, reduced all-cause mortality, and cognitive benefit. Starting after that window, in women who already have subclinical vascular disease, does not produce the same benefit and may carry some risk. Timing matters enormously, and a blanket recommendation against HRT ignores this entirely.

Not all estrogens are the same, and not all progestins are the same. Bioidentical estradiol, delivered transdermally, carries a two to four times lower risk of venous thromboembolism compared to oral estrogen. Oral conjugated equine estrogen contains 4-hydroxy-equilenin, a metabolite with carcinogenic properties not present in pharmaceutical estradiol. Synthetic progestins like MPA increase breast cell proliferation and negate estrogen's cardioprotective effects. Bioidentical progesterone does not increase breast cancer risk and supports sleep, mood, and GABA receptor function as a beneficial side effect. The distinction between the molecules is not semantic — it changes the risk-benefit calculation substantially.

The breast cancer data deserve to be quoted directly rather than summarized loosely. Estrogen alone — in women who have had a hysterectomy — is associated with a reduced risk of breast cancer, with a hazard ratio of 0.77 in the WHI data. Estradiol combined with bioidentical progesterone shows no statistically significant increase in breast cancer risk in the available evidence. Estradiol combined with synthetic progestins shows a clear increased risk — relative risks ranging from 1.26 to 1.69 depending on duration. The conclusion is not that HRT causes breast cancer. The conclusion is that the molecule chosen for the progestogen component matters, and bioidentical progesterone is safer than synthetic alternatives.

What does individualized care actually look like? It starts with a thorough history — not just menopause symptoms but cardiovascular history, clotting history, breast history, family history, bone density status, and an honest conversation about symptoms and quality of life. It continues with shared decision-making, documented clearly, and monitoring every 6 to 12 months. The goal is the lowest effective dose that manages symptoms and provides the protective effects relevant to that individual woman. Some women need only vaginal estrogen. Some need systemic estradiol plus progesterone plus testosterone. Some need DHEA. The protocol should follow the patient, not a standing template.

For bone health specifically, transdermal estradiol at 50 mcg per day with oral progesterone 100 to 200 mg nightly maintains density in most women. For vasomotor symptoms, 25 to 50 mcg transdermal estradiol is the typical starting range. Testosterone at physiologic doses — 150 to 300 mcg transdermal — addresses libido, bone density, and cognition in women who remain symptomatic on estradiol alone. These are not aggressive doses. They are physiologic replacements for what the body no longer produces.

The conversation I want women to be able to have with their providers is an informed one. Not a frightened one. The evidence on bioidentical hormone therapy, when correctly administered within the critical window, is genuinely reassuring. Every woman deserves access to that evidence.

This is not medical advice. I'm sharing clinical experience and evidence to help you have better conversations with your provider.